Protocol Ledger

NCT04651634 · Phase II · ACTIVE NOT RECRUITING

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

Interventional Phase II clinical trial protocol NCT04651634 sponsored by MitoImmune Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-21 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04651634
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04651634
Protocol FieldVerified Registry Value
NCT IdentifierNCT04651634
Consolidated Lead SponsorMitoImmune Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2021-06-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI